Report of Foreign Issuer (6-k)
August 13 2018 - 8:32AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF
1934
For the month of August 2018
Commission File Number 001-34566
China Biologic Products Holdings, Inc.
(Exact name of registrant as specified
in its charter)
18th Floor, Jialong International Building,
19 Chaoyang Park Road
Chaoyang District, Beijing 100125
People’s Republic of China
(+86) 10-6598-3111
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F
x
Form 40-F
¨
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
¨
Note
: Regulation S-T Rule 101(b)(1)
only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
¨
Note:
Regulation S-T Rule 101(b)(7)
only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled
or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which
the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to
be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been
the subject of a Form 6-K submission or other Commission filing on EDGAR.
China Biologic
Products Holdings, Inc. (the “Company”) today announced that its board of directors (the “Board”)
appointed Dr. Bing Li as the chief executive officer of the Company, and Mr. Zhijun Tong, the former acting chief executive
officer, as the president of the Company, effective August 13, 2018. The press release announcing the appointment is included
as Exhibit 99.1 to this Form 6-K.
Upon his appointment
as the chief executive officer, Dr. Bing Li ceased to be an independent director of the Board, and as a result, the eight-member
Board currently contains four independent directors. As a foreign private issuer, the Company has elected to follow Cayman Islands
home country practice regarding the composition of the Board and take an exemption from the requirement under NASDAQ Stock Market
Rule 5605(b) that a majority of the Board be comprised of independent directors.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.
|
|
|
|
|
|
|
Date:
|
August 13, 2018
|
|
By:
|
/s/ David Hui Li
|
|
|
|
|
Name:
|
David Hui Li
|
|
|
|
|
Title:
|
Chairman of the Board of Directors
|
EXHIBIT INDEX
Exhibit Number
|
|
Description
|
99.1
|
|
Press release dated August 13, 2018 titled “China Biologic Names Bing Li as New CEO”
|
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jun 2024 to Jul 2024
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jul 2023 to Jul 2024